Sildenafil is the prototypical agent in a class of selective inhibitors of phosphodiesterase type 5 (PDE5), which are known to enhance nitric oxide-mediated vasodilation in patients with and without heart failure by inhibiting degradation of cyclic GMP, a key intracellular second messenger.(http://www.medscape.com/viewarticle/587004)